Business Wire17h
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
FDA accepts Arrowhead's NDA for plozasiran
Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...
Arrowhead says FDA accepts NDA for investigational plozasiran
Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...
FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease Treatment
Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...
The New England Journal of Medicine9d
Plozasiran for Managing Persistent Chylomicronemia
New research findings on plozasiran, a small interfering RNA, are summarized in a short video.
Finanznachrichten1mon
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
Earlier this month, we submitted our first NDA to the U.S. FDA for investigational plozasiran, paving the way for Arrowhead to potentially launch our first commercial product in 2025, subject to ...